Foretinib
Alternative Names: 1363089; EXEL-2880; GSK 089; GSK 1363089; GSK 1363089G; XL 880Latest Information Update: 05 Nov 2023
At a glance
- Originator Exelixis
- Developer GlaxoSmithKline; National Cancer Institute (Canada)
- Class Anilides; Antineoplastics; Quinolines; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Renal cancer
Most Recent Events
- 01 Mar 2015 GlaxoSmithKline completes a phase I trial for Liver cancer in Hong Kong, Taiwan, and Thailand (NCT00920192)
- 01 Feb 2015 GlaxoSmithKline completes a phase I/II trial in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease) in Canada (NCT01068587)
- 24 Jan 2014 GlaxoSmithKline plans a phase II trial for Non-small cell lung cancer (combination therapy, metastatic disease) in the USA (NCT02034097)